Gasser R W, Herold M, Müller-Holzner E, Müller L C, Salzer G M, Huber H
Klinik für Innere Medizin, Universität Innsbruck.
Dtsch Med Wochenschr. 1988 Nov 4;113(44):1708-13. doi: 10.1055/s-2008-1067876.
Neurone specific enolase (NSE) was measured in serum from 54 patients with untreated bronchial carcinoma. Serum NSE was elevated (greater than 12.5 micrograms/l) in 24 of 31 patients (77.4%) with small cell bronchial carcinoma, but in only 4 of 23 (17.4%) with non-small cell bronchial carcinoma. The median serum NSE level was significantly higher for small cell bronchial carcinoma than for the other forms (23.6 micrograms/l vs. 8.0 micrograms/l; P less than 0.001). NSE levels had a positive correlation to the tumour stage for the small cell tumour: median of 16.5 micrograms/l in "limited disease" (16 cases) and 43.2 micrograms/l in "extensive disease" (15 cases). Serum NSE levels seem to be suitable markers for documenting the course of small cell bronchial carcinoma: 15 patients with tumour regression or remission had normal NSE values while elevated levels were found in 7 of 8 patients with progression. NSE was demonstrated immunohistologically both in small cell and non-small cell bronchial carcinoma tissue, but high NSE levels were predominantly present in small cell carcinomas.
对54例未经治疗的支气管癌患者的血清进行了神经元特异性烯醇化酶（NSE）检测。31例小细胞支气管癌患者中有24例（77.4%）血清NSE升高（大于12.5微克/升），而23例非小细胞支气管癌患者中只有4例（17.4%）升高。小细胞支气管癌患者的血清NSE中位数水平显著高于其他类型（23.6微克/升对8.0微克/升；P<0.001）。NSE水平与小细胞肿瘤的肿瘤分期呈正相关：“局限性疾病”（16例）患者的中位数为16.5微克/升，“广泛性疾病”（15例）患者为43.2微克/升。血清NSE水平似乎是记录小细胞支气管癌病程的合适标志物：15例肿瘤消退或缓解的患者NSE值正常，而8例病情进展的患者中有7例NSE水平升高。在小细胞和非小细胞支气管癌组织中均通过免疫组织化学方法检测到了NSE，但高NSE水平主要存在于小细胞癌中。
